BI
VRDN icon

BVF Inc’s Viridian Therapeutics VRDN Stock Holding History

BVF Inc’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-168,000
Closed -$4.27M – 73
2023
Q1 		$4.27M Sell
168,000
-1,070,974
-86% -$34.3M 0.16% 60
2022
Q4 		$36.2M Sell
1,238,974
-502,866
-29% -$11.6M 1.53% 26
2022
Q3 		$35.7M Sell
1,741,840
-2,172
-0.1% -$39K 1.48% 23
2022
Q2 		$20.2M Hold
1,744,012
– – 0.97% 32
2022
Q1 		$32.2M Sell
1,744,012
-135,400
-7% -$2.6M 1.29% 23
2021
Q4 		$37.2M Buy
1,879,412
+1,075,286
+134% +$20M 1.35% 23
2021
Q3 		$13.2M Buy
804,126
+454,045
+130% +$6.66M 0.52% 49
2021
Q2 		$6.4M Sell
350,081
-113,423
-24% -$1.94M 0.24% 57
2021
Q1 		$7.75M Buy
463,504
+453,757
+4,655% +$8.5M 0.29% 54
2020
Q4 		$160K Buy
+9,747
New +$147K 0.01% 66

Other funds holding VRDN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BVF Inc's VRDN Position: Q2 2023 in Review

BVF Inc sold out of Viridian Therapeutics (VRDN) in Q2 2023, closing a stake of 168,000 shares — an estimated $4.27M sold.

BVF Inc first reported a position in VRDN in Q4 2020 and held it in 10 quarters. The position peaked at $37.2M in Q4 2021. 128 funds tracked by Wall St. Rank hold VRDN as of Q2 2023.

  • BVF Inc reported no remaining Viridian Therapeutics position as of Q2 2023 after selling out during the quarter.
  • BVF Inc sold 168,000 Viridian Therapeutics shares in Q2 2023, an estimated $4.27M.
  • BVF Inc first reported a position in Viridian Therapeutics in Q4 2020 and held it in 10 quarters.
  • BVF Inc's Viridian Therapeutics position peaked at $37.2M in Q4 2021.
  • 128 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2023.

Based on BVF Inc's 13F filing for Q2 2023, filed 14 Aug 2023.